Chapter 4 Recent Advances in Drug Discovery of Histamine H3 Antagonists

Robert L. Hudkins(State Street (United States)), Rita Raddatz
Annual reports in medicinal chemistry
January 1, 2007
10.1016/s0065-7743(07)42004-8
Cited by 41

Related Papers

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
|PubMed|2003|124
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120
Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors
|Expert Opinion on Drug Discovery|2016|113
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
|Molecular Cancer Therapeutics|2007|112